ABSTRACT
Objective:To invetigate the use of targeted anticancer drugs in our hospital during 2011-2013 to provide reference for the clinical rational drug use. Methods:The utilization of anti-tumor molecular targeted drugs in our hospital during 2011-2013 was retrospectively analyzed in respect of consumption sum, DDDs and DDC. Results:The proportion of consmption sum of anti-tumor mo-lecular targeted drugs in the total consumption sum was increased year by year, and that in 2012 and 2013 was over 60%. Protease ki-nase inhibitors accounted for 41. 29%-73. 41% in the consumption sum of anti-tumor molecular targeted drugs; monoclonal antibody accounted for 19. 40%-30. 88%; the other drugs accounted for 7. 19%-27. 83%. The consumption sum and the number of receiving medication patients of rituxan and cetuximab were not synchronized well, and the patients were born the higher cost. Conclusion:The use of anti-tumor molecular targeted drugs in our hospital is increased year by year, and the oral administration of anti-tumor molecular targeted drugs is with especially wide application.